Icon, Ireland’s largest provider of clinical research for drugmakers, lowered its 2009 forecast for annual earnings and revenue.
Icon expects earnings per share this year to be between $1.38 and $1.44 and revenue to be between $880 million and $900 million, the Dublin-based company said today.
Icon previously forecast annual earnings in the range of $1.40 to $1.52 and net revenue of between $930 million and $980 million.
The company, which tests new medicines for pharmaceutical and biotechnology companies, said in April that 2009 earnings would be at the lower end of the range given in January due to a “difficult market.”
It also said at the time it needed “solid business wins and strong cost control” to achieve the targets.
The group today reported second-quarter net income of $22.8 million, up from $18.8 million in the year-earlier period.
Bloomberg